All In Biotech

Drug Trial Radar · NCT06944925

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Patients With COPD or CRSwNP

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

May 8, 2025

Primary completion

Jan 31, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Bambusa TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Randomized study of single and multiple doses of BBT002 in healthy volunteers and in adult patients with chronic obstructive pulmonary disease (COPD) or chronic rhinosinusitis with nasal polyps (CRSwNP).

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • BBT002Drug

    BBT002 will be administered.

  • PlaceboDrug

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events following single and multiple administration of BBT002Time frame: Parts A and E - up to 141 days post first dose administration; Parts B, C, D, F, and G - up to 169 days post first dose administration
  2. Number of participants with change in Laboratory assessmentsTime frame: Parts A and E - up to 141 days post first dose administration; Parts B, C, D, F, and G - up to 169 days post first dose administration
  3. Number of participants with change in vital sign measurements following dose administration.Time frame: Parts A and E - up to 141 days post first dose administration; Parts B, C, D, F, and G - up to 169 days post first dose administration
  4. Number of participants with change in physical examination following dose administration.Time frame: Parts A and E - up to 141 days post first dose administration; Parts B, C, D, F, and G - up to 169 days post first dose administration
  5. Number of participants with change in 12-lead ECG readingsTime frame: Parts A and E - up to 141 days post first dose administration; Parts B, C, D, F, and G - up to 169 days post first dose administration

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • Equity Medical Bowling Green

    Bowling Green, Kentucky · Recruiting

  • Equity Medical - Owensboro

    Owensboro, Kentucky · Not yet recruiting

  • Equity Medical LLC

    New York, New York · Recruiting

  • Momentum Clinical Research

    Brisbane, Australia · Recruiting

  • Linear Clinical Research

    Perth, Western Australia, Australia · Recruiting

  • Aleksandre Aladashvili Clinic LLC

    Tbilisi, Georgia · Recruiting

  • Geo Hospitals Tbilisi Multiprofile Medical Center

    Tbilisi, Georgia · Recruiting

  • LEPL The First University Clinic of Tbilisi State Medical University

    Tbilisi, Georgia · Recruiting

  • Ltd Aversi Clinic

    Tbilisi, Georgia · Recruiting

  • Momentum Clinical Research

    Pukekohe, New Zealand · Recruiting

  • Momentum Clinical Research

    Wellington, New Zealand · Recruiting

  • Momentum Clinical Research Hamilton

    Rotorua, Hamilton, New Zealand · Not yet recruiting

  • Uniwersyteckie Centrum Kliniczne Osrodka Badan Klinicznych Wczesnych Faz

    Gdansk, Poland · Not yet recruiting

  • Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o.

    Krakow, Poland · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.